Global COVID-19 Diagnostics Market

Global COVID-19 Diagnostics Market Size, Share, Growth Analysis, By Sample Type(Oropharyngeal swabs, nasopharyngeal), By Technology(Polymerase chain reaction, Enzyme-linked immunoassay (ELISA)), By End users(Laboratories, hospitals) - Industry Forecast 2024-2031


Report ID: SQMIG35B2067 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 92 | Figures: 76

Global COVID-19 Diagnostics Market Insights

COVID-19 Diagnostics Market size was valued at USD 97.4 billion in 2021 and is poised to grow from USD 95.2 billion in 2022 to USD 50.1 billion by 2030, growing at a CAGR of 7.7% in the forecast period (2023-2030).

Covid-19 (coronavirus disease) is a highly contagious viral infection caused by the severe acute respiratory syndrome. COVID-19 had a severe impact on the population of the world, causing more than 6 billion deaths globally and becoming the most severe worldwide health crisis. The first case of COVID-19 was reported in Wuhan, Hubei Province, China, in late December 2019. COVID-19 rapidly spread across the world in a short period of time, and the world health organization (WHO) declared it is a global pandemic on 11 march 2020.

Health services around the world are struggling to manage the population of COVID-19 patients, and researchers are looking for solutions. On the other hand, all business and operation sectors witnessed severe economic loss due to imposition of lockdown regulations in order to stop the spread of the virus. Globally, GDP has fallen, unemployment has risen and inflation has risen. The high rate of coronavirus transmission has led to a rapid increase in COVID-19 cases and deaths worldwide and has increased the need for diagnosis and treatment. However, a key challenge to achieving successful solutions is the lack of information on the new virus, such as biological and genetic information, and the duration of immunity in recovered patients, which are important for developing safe and effective treatments.  According to some statistics, the total number of cases witnessed a spike with 33,556,252 patients testing positive as of 28th September 2020 to 55,961,380 patients on 17th November 2020.

In terms of treatment options, the industries are focused on developing immunotherapy, vaccines, antiviral, cell-based therapies, and plasma therapies. Currently, about 205 different therapies and 124 vaccines are in the development stage. Antibodies, protein-based vaccines, Antivirals, RNA-based vaccines, non-replicating viral vectors, and cell-based therapies are several most significant research topics that fall under the COVID-19 Diagnostic study category. Vaccines and antivirals are the most extensively researched treatment options currently being investigated by researchers around the world.

US COVID-19 Diagnostics Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

COVID-19 Diagnostics Market size was valued at USD 97.4 billion in 2021 and is poised to grow from USD 95.2 billion in 2022 to USD 50.1 billion by 2030, growing at a CAGR of 7.7% in the forecast period (2023-2030).

The nature of competition in this market is very intense owing to the presence of multiple players. Partnerships with companies that provide free technology and investment to increase the production capacity of potential therapies are key strategies adopted by industry players to strengthen their market position. ' F. Hoffmann-La Roche AG ', ' Abbott Laboratories ', ' Thermo Fisher Scientific Inc. ', ' Becton, Dickinson and Company ', ' Siemens Healthineers AG ', ' Danaher Corporation ', ' QIAGEN N.V. ', ' Bio-Rad Laboratories, Inc. ', ' Hologic, Inc. ', ' Ortho-Clinical Diagnostics, Inc. ', ' Cepheid ', ' Beckman Coulter, Inc. ', ' GenMark Diagnostics, Inc. ', ' PerkinElmer, Inc. ', ' Sysmex Corporation ', ' Seegene Inc. ', ' BioFire Diagnostics, LLC ', ' BioMérieux SA ', ' ThermoGenesis Holdings, Inc. ', ' Meridian Bioscience, Inc. '

To deal with the COVID-19 crisis, governments across the world have implemented lockdowns. The government invested in the COVID-19 crisis and has been supporting health and life science industries in developing rapid treatment. FDA announced an emergency use authorization (EUA) pathway for the emergency use of therapies that help in the treatment of COVID-19. Several pharmaceuticals, biotechnology, and biopharmaceutical firms granted EUA approval which supports further clinical studies on therapy.

In vitro diagnostic, companies and governments have focused on developing more reliable tests, which provides faster results at lower costs. By July 2021, more than 500 COVID-19 POC diagnostic tests were available in the market.

The market size of North America is USD 11.97 billion in 2021, thus registering the fastest growth rate. The market in the region is expected to grow at a substantial level because of the sudden rise in COVID-19 cases and deaths in this region, so the demand for diagnosis and treatment increases.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global COVID-19 Diagnostics Market

Product ID: SQMIG35B2067

$5,300
BUY NOW GET FREE SAMPLE